A Randomized Placebo Controlled Study of OSI-744 (Erlotinib HCl, Tarceva[TM]) in Patients With Incurable Stage IIIB/IV Non-Small Cell Lung Cancer Who Have Failed Standard Therapy for Advanced or Metastatic Disease

Trial Profile

A Randomized Placebo Controlled Study of OSI-744 (Erlotinib HCl, Tarceva[TM]) in Patients With Incurable Stage IIIB/IV Non-Small Cell Lung Cancer Who Have Failed Standard Therapy for Advanced or Metastatic Disease

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Mar 2016

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Pharmacogenomic; Registrational; Therapeutic Use
  • Sponsors OSI Pharmaceuticals
  • Most Recent Events

    • 10 Jan 2012 Pharmacogenetic analysis published in the Journal of Thoracic Oncology.
    • 16 Feb 2010 Cost effectiveness results published in the Journal of the National Cancer Institute.
    • 31 Jul 2009 Results have been reported at the 13th World Conference on Lung Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top